Taiga Biotechnologies was founded to develop novel approaches to treat hematological diseases, including cancers, immunodeficiencies and autoimmune conditions. Our three-pronged approach combines novel breakthroughs in cellular, biologic and small molecule approaches to treat and manage these diseases.

Welcome to Taiga Biotechnologies.

Latest News

Taiga's technology and its applications featured in University of Colorado Cancer Center Quarterly Update.

Taiga’s Scientific Advisory Board Chairman, Yosef Refaeli, to present Taiga’s technology platform at Americas Antibody Congress 2009. September 21-23. Washington, D.C.

September 19, 2008: Taiga Biotechnologies, Inc. received its second small business innovation research grant from the Department of Health and Human Services, National Heart, Lung, and Blood Institute . The grant will be used to further develop the proprietary technology for generating cell based therapies for the treatment of human disease. Read the abstract.

August 7, 2008: Taiga Biotechnologies, Inc. received its first small business innovation research grant from the Department of Health and Human Services, National Institute of Allergy and Infectious Disease. The grant will be used to further develop the proprietary technology to rapidly generate human therapeutic antibodies against influenza. Read the abstract.

June 24, 2008: International reports by Forbes, U.S. News and World Report and others describe recent lymphoma discovery made by Taiga founders.
Forbes | U.S. News and World Report

Local CBS news conducts an exclusive interview with Dr. Yosef Refaeli about the stem cell technology discovered at National Jewish Medical and Research Center.
The following link contains the entire interview which aired on CBS channel 4 on Tuesday, November 27, 2007. Watch video.